Jump to content
RemedySpot.com

Weight-loss Drugs - What Works?

Rate this topic


Recommended Posts

Posted

Weight Loss Drugs: What Works?

A. Stokowski, RN, MS

Posted: 12/13/2010

Wanted: A Pill That Melts Fat

As Americans become more obese and the associated health problems reach epidemic

proportions, the need for a safe and effective weight loss drug has become

urgent. Over the years, this quest has been marked with short-lived triumphs and

many defeats, leaving patients and clinicians with less than ideal weapons in

the fight against obesity.

The few drugs that have actually reached the market in recent years promote

weight loss either by boosting the body's basal metabolic rate, blocking the

absorption of dietary fat, or suppressing appetite.People who take these drugs

typically lose weight for the first 6 months until they reach a plateau that

can't be surpassed without increasing exercise or caloric restriction.The

problems with many of these agents have been a lack of proven long-term safety,

and the fact that when such drugs are stopped, the weight is usually regained.

Most clinicians are aware that pharmacotherapy is not indicated as a first-line

therapy for obesity, and should not be initiated until all nonpharmacologic

attempts at weight loss (diet, exercise) have failed.[1] It is also important to

evaluate other medications that the patient may already be taking, as some may

promote weight gain (eg, sulfonylureas, thiazolidinediones, and insulin),

thereby negating the effects of anti-obesity drugs.[2]

The decision to prescribe a weight-loss drug involves a careful assessment of

the risks and benefits.[3] As a general rule, an effective regimen should help

patients lose at least 4 pounds in the first 4 weeks, or 5% of baseline weight

in the first 3 months on therapy.

As researchers continue searching for an ideal weight-loss agent, clinicians

must work with available therapies while awaiting newer drugs in the pipeline.

Currently on the Market

Two classes of weight-loss agents are currently available by prescription:

noradrenergic agents for short-term weight loss and a lipase inhibitor for

long-term weight loss.

Phentermine

Phentermine is US Food and Drug Administration (FDA)-approved for short-term (up

to 12 weeks) treatment of obesity and is the most widely prescribed weight-loss

drug in the United States.[4] Phentermine is an adrenergic reuptake

inhibitor,[5] stimulating the sympathetic nervous system to release

norepinephrine, one of the neurotransmitters involved in modulating food intake.

Phentermine suppresses appetite and induces satiety much like amphetamines, but

has little effect on dopamine transmission, mitigating its abuse potential.[1]

Because its effects last about 12 hours, phentermine should be taken in the

morning. When used in combination with diet and exercise, phentermine has

produced an average 3.6 kg greater weight loss than placebo.[6]

Phentermine is the relatively " safe half " of the formerly popular (but no longer

on the market) weight-loss drug phentermine-fenfluramine (phen-fen).

Fenfluramine (but not phentermine) was linked to pulmonary hypertension and

valvular heart disease. Phentermine alone was found to be an effective

anorectic, and it is still available as a prescription drug in 15 mg to 37.5 mg

strengths[7] (although many manufacturers discontinued it).

Adverse effects include irritability, nervousness, restlessness, dry mouth,

insomnia, constipation, and headache, but it has also been associated with

hypertension, tachycardia, and palpitations, so it should not be taken by

patients with cardiovascular disease or significant hypertension. Blood pressure

should be monitored during therapy.

Diethylpropion

Like phentermine, diethylpropion is a noradrenergic agent with a similar

mechanism of action (releasing and inhibiting the uptake of neurotransmitters

norepinephrine and dopamine). Diethylpropion is available in 25-mg standard or

75-mg extended-release formulations, and is approved for short-term treatment of

obesity.

In a recent study, 69 obese healthy adults were treated with diet and

diethylpropion or diet and placebo.[8] After 6 months, the diethylpropion group

lost an average of 9.8% of initial body weight vs 3.2% in the placebo group (P <

..0001). In 1 year, the mean weight loss in patients taking diethylpropion was

10.6%. Dry mouth and insomnia were the most frequent adverse events.[8]

Benzphetamine and Phendimetrazine

Two other sympathomimetic drugs benzphetamine and phendimetrazine are still

available by prescription for short-term weight loss. These drugs also act

centrally, releasing dopamine and norepinephrine, resulting in appetite

suppression, increased blood pressure, and increased heart rate. As schedule III

drugs, however, benzphetamine and phendimetrazine have more potential for

addiction and therefore are prescribed less often.[9]

All sympathomimetic drugs stimulate the central nervous system, and can increase

blood pressure and heart rate, while releasing glycerol and free fatty acids.[9]

Still, in a recent survey of obesity specialists in the United States, these

were among the most frequently prescribed drugs in the clinical treatment of

obesity. Most respondents (97%) reported prescribing phentermine, 64% prescribed

diethylpropion, and 60% prescribed phendimetrazine.[4]

Orlistat

A gastrointestinal and pancreatic lipase inhibitor, orlistat was approved in

1999 as the first in a new class of anti-obesity agents. In the gastrointestinal

tract, orlistat binds to gastric and pancreatic lipases, preventing these

enzymes from hydrolyzing dietary fat into absorbable free fatty acids.[1] When

not absorbed, triglycerides are excreted in the feces, along with cholesterol

and fat-soluble vitamins. Taken with meals, orlistat can block the absorption of

30% of ingested fat.[5] In this manner, orlistat reduces caloric intake and may

have additional benefits.

A Cochrane meta-analysis[10] of 11 randomized controlled trials of orlistat

found that overweight and obese individuals who took orlistat had a mean weight

loss of 2.9 kg (2.9%) more than those who took placebo. Compared with placebo,

orlistat also significantly reduced waist circumference, body mass index (BMI),

blood pressure, fasting glucose, and hemoglobin A1c concentrations in patients

with diabetes, as well as total cholesterol, low-density lipoprotein cholesterol

(LDL-C), and high-density lipoprotein cholesterol (HDL-C) concentrations.[2]

Adverse effects of orlistat are fairly common, affecting 15%-30% of patients and

considered unpleasant and unacceptable by some patients.[2] These include

steatorrhea, bloating, fecal urgency, fecal incontinence, and oily stools.[5]

Orlistat might also interfere with the absorption of fat-soluble vitamins,

including vitamins A, D, E, and K, so it has been suggested that patients taking

orlistat should also take a multivitamin supplement containing these

micronutrients, at least 2 hours before or after the administration of orlistat.

Concerns about a link between orlistat and colon cancer, as well as possible

liver damage, are currently being investigated.[11] Orlistat may also interfere

with the absorption, and therefore the effectiveness, of other drugs the patient

is taking, such as amiodarone and cyclosporine, and through its effect on

vitamin K, it can prolong bleeding in patients taking warfarin.[11] This class

of drug should probably be avoided in patients with gastrointestinal disease or

malabsorption syndromes.[2]

Orlistat is currently available as a prescription drug (Xenical® 120 mg) or an

over-the-counter weight loss supplement (Alli® 60 mg). Although it is approved

for long-term weight loss, orlistat's somewhat low tolerability and high cost

may limit its long-term use.

Withdrawn or Awaiting Approval

The fall of 2010 was a discouraging time for those who are desperate for a new

obesity treatment, including patients who say they would be willing to accept

some risk if they were able to lose weight. Hopes were raised and then dashed as

promising therapies slipped off the horizon in October, just after an

established drug was withdrawn from the market. But companies touting the new

therapies are continuing to collect safety information that they hope will

satisfy regulators and ultimately allow them to sell their products.

Sibutramine

Abbott, maker of the sibutramine product Meridia®, issued a voluntary product

recall in October upon being asked by the FDA to stop marketing Meridia in the

United States; this followed reports of an increased risk for heart attack and

stroke in Meridia users. Meridia had already been recalled earlier in Canada and

Europe.

Sibutramine hydrochloride is a centrally acting monoamine reuptake inhibitor,

affecting primarily serotoninand norepinephrine, and to a lesser extent,

dopamine.[1] Originally used to treat depression, patients taking sibutramine

experienced weight loss as an unexpected effect. Although diminished hunger and

increased satiety are the most likely mechanisms of weight loss, sibutramine may

also increase thermogenesis, thus increasing energy expenditure by increasing

metabolism.[1]

The Sibutramine Cardiovascular OUTcomes (SCOUT) trial was a 6-year study of

10,000 patients, conducted to assess cardiovascular safety in high-risk

patients. It showed that, after 5 years (the end of the trial), the average

difference in body weight between patients taking Meridia and those taking a

placebo was about 2.5%. On long-term follow-up, a 16% increased risk for

nonfatal heart attacks and nonfatal strokes was seen in patients with

pre-existing cardiovascular risk factors.[12] This was considered by some to be

an unacceptable benefit to risk ratio. However, the manufacturer asserts that

the increased cardiovascular events occurred primarily in patients with

underlying cardiovascular disease, a patient population in whom Meridia is

contraindicated according to enhanced labeling initiated earlier this year.[13]

Lorcaserin

Lorcaserin is an anti-obesity drug of the 5-HT2C agonist class. The stimulation

of specific central serotonin receptors suppresses appetite and induces a

feeling of satiety. Lorcaserin is highly selective for the 5-HT2C receptor,

which modulates fat and caloric intake.[14] Signaling through the 5-HT2A and

5-HT2B receptors (found on cardiac valves), however, is minimal.[2]

In a large trial (3182 patients), those who took lorcaserin lost an average of

5.8% of their baseline body weight compared with 2.2% in those who took placebo

(P < .001).[15] Nearly half of the patients taking lorcaserin lost 5% or more of

their baseline body weight, compared with 20% of those taking placebo, and more

of the lorcaserin patients maintained their weight loss after the study had

ended. Very few patients in the lorcaserin group failed to lose weight.

Other improvements associated with lorcaserin were: reduced BMI and waist

circumference; lower fasting glucose, insulin, and A1c levels; and lower total

cholesterol, LDL cholesterol, and triglycerides. However, despite beneficial

effects on risk for cardiovascular disease (reduced C-reactive protein,

fibrinogen level, systolic and diastolic blood pressure, and heart rate), the

FDA voted against approval of lorcaserin in October, citing concerns about

lorcaserin-induced valvular heart disease (as well as brain and breast tumors)

in declining to recommend lorcaserin for the treatment of obesity.[16]

The agency requested additional data about lorcaserin from drug maker Arena

Pharmaceuticals, and the company says it will meet with the FDA before the end

of the year, partly to discuss new, " encouraging " data regarding lorcaserin's

effects on obese patients with diabetes.

Phentermine/Topiramate

Qnexa® (made by Vivus, Inc.) combines low-dose phentermine with a

controlled-release form of topiramate, an antiepileptic drug often used for the

prevention of migraine headache. Topiramate inhibits excitatory

neurotransmissions by blocking voltage-gated sodium channels,[17] and is

sometimes prescribed as monotherapy for weight loss.[4] Topiramate reduces

hunger and promotes weight loss in a dose-dependent fashion, but the peripheral

and central nervous system effects (parasthesias, memory impairment, taste

disturbance) are significant and intolerable in some patients.[18] Topiramate

has the added advantage of having mood-stabilizing properties.[5]

Harnessing the effects of the 2 different but complementary mechanisms of

phentermine and topiramate allows the use of lower doses of each agent, which

should increase safety.[19] This drug combination reportedly induces substantial

weight loss, an average of about 10% after 1 year, and significantly reduces

systolic blood pressure. Patients taking lower doses of the drug combination

lose less weight, but that is still more than those taking placebo.

Despite evidence of effectiveness in phase 3 trials extending to 1 year, the FDA

voted against approval of Qnexa in October, expressing concerns about adverse

effects associated with its use, including cognitive disorders, metabolic

acidosis, increased heart rate, and birth defects, suggesting possible

teratogenicity.

Before Qnexa can be approved, the FDA has requested further evidence of its

safety.[19] If approved, it would be a schedule IV drug due to the phentermine

component.

Naltrexone/Bupropion

Contrave®, another new dual anti-obesity agent, is the combination of the

antidepressant bupropion and sustained-release (SR) naltrexone, a drug used to

treat alcoholism and other addictions. Bupropion, approved for both depression

and smoking cessation, also increases dopamine levels at specific receptors in

the brain, which is believed to be responsible for its appetite-reducing

effects.[20] These 2 drugs work on the brain reward system and the hunger

centers in the hypothalamus, and are believed to be synergistic in reducing food

intake.[21]

If approved, this combination therapy could be useful for patients who have

issues with food craving. When used with a mild hypocaloric diet and with

exercise instruction in overweight or obese patients, it is associated with

greater weight loss and greater improvement in several cardiometabolic risk

factors compared with placebo.[22] Combination treatment was generally well

tolerated; adverse effects included insomnia, nausea, headache, dry mouth, and a

small and transient increase in systolic and diastolic blood pressure.[22]

Contrave has not yet been reviewed by the FDA, but phase 3 clinical trials have

been completed. The manufacturer, Orexigen, reports that Contrave met all of its

primary endpoints for weight loss in these trials, even in patients with

diabetes, it also was associated with improvements in cardiometabolic risk

markers such as waist circumference, HDL-C levels, and triglyceride levels.[23]

Contrave is up for review by the FDA's Endocrinologic and Metabolic Drugs

Advisory Committee in December 2010.[23]

The fate of this anti-obesity agent will not be known until sometime in 2011.

In the Pipeline

Zonisamide/Bupropion

In clinical trials for the relatively new antiepileptic zonisamide, an

unanticipated effect was weight loss. It has, therefore, been studied for its

potential as a weight-loss agent, either in monotherapy or in combination with

other agents such as bupropion. Zonisamide has sodium and calcium channel

blocking activity, as well as dose-dependent biphasic dopaminergic and

serotonergic activity. Empatic™ (made by Orexigen) is a fixed-dose combination

of a proprietary formulation of zonisamide SR and bupropion SR.

In trials at Duke University, zonisamide alone with a hypocaloric diet was shown

to be more effective in reducing weight than placebo.[24] The same investigators

have conducted a short-term, open-label trial of treatment with zonisamide and

bupropion, finding that the combination resulted in more weight loss than

zonisamide alone.[25] Fatigue, drowsiness, sedation, nausea, and cognitive

impairments (difficulty concentrating, memory problems, speech and language

difficulties) have all been reported with zonisamide use.[25]

The manufacturer of Empatic recently reported that in phase 2b trials, patients

who took the drug for 24 weeks lost 9.9% of their baseline body weight compared

with 1.7% for patients taking placebo, without evidence of a plateau.

Improvements in waist circumference, triglycerides, fasting insulin, and blood

pressure were also reported.[23] Phase 3 trials are now planned.

Tesofensine

Tesofensine (made by NeuroSearch) is a triple monoamine reuptake inhibitor that

blocks the presynaptic uptake of norepinephrine, dopamine, and serotonin.[17]

Originally being studied for neurodegenerative conditions such as Parkinson and

Alzheimer diseases, unintended weight loss was observed in individuals treated

with the drug.[26]

The mechanisms through which tesofensine leads to weight loss are a pronounced

effect on appetite suppression and increased energy expenditure.[27] In phase 2

clinical trials with tesofensine in obese patients, dose-related reductions in

body weight, body fat, and waist circumference, as well as improvements in other

obesity-related measures, were observed. Minor adverse events included

elevations in heart rate and significant increases in blood pressure only at the

highest tested dose.[28] The drug is soon to be tested in phase 3 clinical

trials.[26]

Cetilistat

Cetilistat is a new lipase-inhibitor with a similar mode of action to orlistat,

inhibiting pancreatic lipase and blocking digestion and absorption of dietary

fat, so that it can be eliminated unchanged with the stool. Cetilistat has

completed a 12-week phase 2b trial in obese patients, demonstrating weight loss

consistent with other obesity medications and significant improvements in other

obesity-related parameters.[29] Unpleasant adverse effects, including flatus

with discharge and oily spotting, were reported by fewer than 3% of patients

using cetilistat.

It is probable that, like orlistat, cetilistat will also block the absorption of

fat-soluble vitamins, and this possibility was raised by the FDA in 2009,

cautioning that cetilistat could " lead to malabsorption of nutrients and vitamin

deficiency. " [30] Cetilistat has now been cleared to conduct phase 3 trials in

patients with obesity.

Pramlintide/Metreleptin

The combination of these 2 agents represents a novel integrated neurohormonal

approach to obesity.[31] Pramlintide is an analogue of amylin, a hormone

secreted by pancreatic beta cells along with insulin. Exogenous amylin can

increase the absorption of glucose, slow gastric emptying, and by binding to

hypothalamic receptors, promote satiety, reduce food intake and elicit weight

loss. Metreleptin is recombinant methionine human leptin. Leptin is a

neurohormone secreted by adipocytes that also binds to receptors in the

hypothalamus to promote satiety. When someone reduces dietary intake to lose

weight, leptin levels drop, and this triggers a host of counter-regulatory

responses aimed at maintaining body weight. Administration of metreleptin

restores leptin concentrations and attenuates the effects of

counter-regulation.[31]

Pramlintide is already an approved drug in the treatment of diabetes.

Metreleptin has been tested as monotherapy for obesity/weight loss, but failed

because of the development of leptin resistance. However, these 2 hormones are

believed to act synergistically to reduce food intake and body weight.

Mildly and moderately obese patients (without diabetes) who took this

combination lost about 13% of baseline body weight in 24 weeks with no

weight-loss plateau, significantly more than was seen with either drug

administered as a single agent. Patients who continued treatment with

pramlintide/metreleptin for a total of 52 weeks exhibited sustained weight loss,

whereas those who received placebo during the extension study regained almost

all of their lost weight. The combination therapy appeared to be generally well

tolerated. The most common adverse effect was nausea.[31]

Pramlintide/metreleptin combination is an injectable therapy, which may limit

its application in the general obese population.

Potential Future Therapies

ZGN-433, a methionine aminopeptidase inhibitor, targets the adipose tissue

rather than the central nervous system. This class of medication essentially

works by restoring control of adipose tissue lipolysis, ketogenesis, food

intake, and fat synthesis. ZGN-433 is believed to stimulate adipose tissue to

convert stored triglycerides into free fatty acids that can be used for

energy.[32]

ZGN-433 is still in the early stages of development but has shown promise in

rodent studies. A safety and tolerability study in humans is in progress.

Another novel therapy that may have a role in weight loss is ezlopitant, a

neurokinin receptor-1 (NK1R) antagonist. The NK1R system has been implicated in

both learned appetitive behaviors and addiction to alcohol and opioids; recent

evidence from rodent studies suggests that ezlopitant reduces the appetite for

sucrose as well, thus decreasing the consumption of sweetened foods and

drinks.[33] It has been suggested that sweet foods and drinks can be addictive

in the same way as alcohol, explaining the suppressant effects of ezlopitant.

The antidiabetes drugs represent another possible drug class to mine for

potential weight-loss effects and for possible development as dual

diabetes/obesity agents. Metformin, a biguanide approved for the treatment of

type 2 diabetes, causes weight loss by reducing hepatic glucose production and

intestinal absorption from the gastrointestinal tract, and enhancing insulin

sensitivity.[34]

Liraglutide (Victoza®), another drug that is already approved for the treatment

of type 2 diabetes, induces moderate weight loss of approximately 2-3 kg.[35]

The glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide

are newer medications for diabetes that have favorable effects not only on

glycemic control but also on weight loss.[3] Although some of these agents might

not induce enough weight loss to qualify as anti-obesity agents, they could

prove useful for overweight individuals who have diabetes.[34]

Final Thoughts on Anti-Obesity Pharmacotherapy

Obesity is a chronic, relapsing, biologic condition that may well require

long-term pharmacotherapy, in the same manner as hypertension and diabetes. To

date, however, the average amount of weight lost with most pharmacologic agents

has been modest at best, and the typical patient will most likely remain

overweight or obese even with ongoing treatment.[12]

Weight-loss drugs are expensive; neither Medicare nor most insurance plans cover

them. In addition, most are associated with adverse effects. Therefore, meeting

efficacy criteria for weight loss is not good enough for anti-obesity agents

that will be taken by millions of people for many years. The benefits of any

weight-loss drug must outweigh the risks, and safety is the overriding

consideration.

It is too early to tell whether some of the novel weight loss drugs still in

development will offer greater efficacy and safety. What is certain is that drug

developers will continue to search for the Holy Grail of anti-obesity drugs as

the world's girth continues to expand.

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...